Antismoking groups sued the US government over the long-awaited menthol cigarette ban; the fill rate for Adderall and Vyvanse dropped more than 10% in 2 years despite soaring demand; the Biden administration has responded to offers from the manufacturers of drugs selected for Medicare pricing negotiations.
Antismoking groups sued the US government on Tuesday over the long-awaited menthol cigarette ban, which the Biden administration has been delaying for months, according to the Associated Press. This lawsuit is the latest effort to force the government to ban menthol cigarettes, which are disproportionately used by young people and Black smokers; advocates are concerned that the federal plan could be derailed by election-year politics. Late last year, White House officials said they would take until March to review the rule. After the March deadline passed, 3 nonprofit groups, including Action on Smoking and Health, filed their lawsuit in a California federal court. A lawyer who helped file the lawsuit said the government will have about 2 months to respond.
A recent analysis found that the fill rate for Adderall and Vyvanse, 2 commonly prescribed drugs for attention-deficit/hyperactivity disorder (ADHD), dropped more than 10% in 2 years despite soaring demand, according to Axios. The ADHD drug shortage has occurred for nearly 18 months with no clear end in sight and is among many generic medicine shortages in recent years. Likely drivers of the shortages include drug production caps and pandemic-driven demand increases. The problem has recently been getting attention on Capitol Hill and from federal regulators. On Tuesday, HHS said in a white paper that statutory changes and more funding are needed for “more impactful and enduring solutions” than the ones it has already taken to address the shortages.
The Biden administration announced Tuesday that it has responded to offers from the manufacturers of 10 high-cost drugs selected for the Medicare drug pricing negotiations but provided no further details, according to Reuters. CMS picked the first 10 drugs for negotiation in August and sent its initial price offers in February. The companies had until March 1 to respond, and all did so. Each company can meet with CMS up to 3 times for further negotiations before a final price is announced on August 1. However, the negotiated prices will not come into effect until 2026. The drugs selected for negotiation are manufactured by Bristol Myers Squibb, Johnson & Johnson, Eli Lilly, Novo Nordisk, Pfizer, Merck & Co, AbbVie, Amgen, and Boehringer Ingelheim.
Congress Urged to Repeal Comstock Act Threatening Reproductive Rights and Public Health
May 16th 2024In a joint letter addressed to Congress, Healthcare Across Borders, Take Back the Court Action Fund, and UltraViolet Action called out the resurgence of the Comstock Act, urging immediate action to repeal this century-old law that threatens reproductive rights and public health in the US.
Read More
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
May 7th 2024On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
Listen
Panel Addresses Minority Physician Shortage, Maternal Health at Senate Committee Hearing
May 15th 2024The senate hearing held by the US Senate Committee on Health, Education, Labor, and Pensions, led by Sen. Bernie Sanders (I, Vermont), chairman of the committee, and ranking member Sen. Bill Cassidy, MD, (R, Louisiana), addressed the critical issue of physician and health care worker shortages, as well as the maternal health crisis, in the US.
Read More
House lawmakers are expected to advance a contracting ban today on 5 Chinese research firms; US government officials temporarily relaxed strict guidelines on how laboratories handle, store, and transport H5N1 bird flu samples; a recent report found that the number of abortions occurring in the US continued to grow despite bans.
Read More